Sirdalud Retard 12 mg depotkapsler, hårde Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sirdalud retard 12 mg depotkapsler, hårde

novartis healthcare a/s - tizanidinhydrochlorid - depotkapsler, hårde - 12 mg

Zercepac Den Europæiske Union - dansk - EMA (European Medicines Agency)

zercepac

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastiske midler - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. før kemoterapi skal have omfattet mindst en antracyklin og en taxane medmindre patienter, der er uegnede til disse behandlinger. hormon-receptor-positive patienter skal også have undladt hormonbehandling, medmindre patienter, der er uegnede til disse behandlinger.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. i kombination med docetaxel til behandling af de patienter, der ikke har fået kemoterapi for deres metastatisk sygdom. i kombination med en aromatase inhibitor til behandling af postmenopausale patienter med hormon-receptor positiv mbc, der ikke tidligere er behandlet med trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). følgende kirurgi, kemoterapi (neoadjuverende eller adjuvans) og strålebehandling (hvis relevant). efter adjuverende kemoterapi med doxorubicin og cyclophosphamid, i kombination med paclitaxel eller docetaxel. i kombination med adjuverende kemoterapi, der består af docetaxel og carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. præcise og validerede analyse metoder, der bør anvendes.

Dasatinib Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Pioglitazone Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

pioglitazone accord

accord healthcare s.l.u. - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazon er angivet i behandlingen af type-2-diabetes mellitus:som monotherapyin voksne patienter (specielt overvægtige patienter), der ikke er tilstrækkeligt kontrolleret med diæt og motion, for hvem metformin er uegnet på grund af kontraindikationer eller intolerance. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt.

Allopurinol "DAK" 100 mg tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

allopurinol "dak" 100 mg tabletter

orifarm healthcare a/s - allopurinol - tabletter - 100 mg

Cisplatin "Accord" 1 mg/ml koncentrat til infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cisplatin "accord" 1 mg/ml koncentrat til infusionsvæske, opløsning

accord healthcare b.v. - cisplatin - koncentrat til infusionsvæske, opløsning - 1 mg/ml

Diovan Comp 160 mg/12,5 mg 160 mg+12,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

diovan comp 160 mg/12,5 mg 160 mg+12,5 mg filmovertrukne tabletter

novartis healthcare a/s - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 160 mg+12,5 mg

Diovan Comp 160 mg/25 mg 160 mg+25 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

diovan comp 160 mg/25 mg 160 mg+25 mg filmovertrukne tabletter

novartis healthcare a/s - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 160 mg+25 mg

Diovan Comp 320 mg/12,5 mg 320 mg+12,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

diovan comp 320 mg/12,5 mg 320 mg+12,5 mg filmovertrukne tabletter

novartis healthcare a/s - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 320 mg+12,5 mg

Diovan Comp 320 mg/25 mg 320 mg+25 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

diovan comp 320 mg/25 mg 320 mg+25 mg filmovertrukne tabletter

novartis healthcare a/s - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 320 mg+25 mg